Last reviewed · How we verify

Leqvio — Competitive Intelligence Brief

Leqvio (INCLISIRAN) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Proprotein convertase subtilisin/kexin type 9 Metabolic Oligonucleotide Live · refreshed every 30 min

Target snapshot

Leqvio (INCLISIRAN) — Novartis. Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Leqvio TARGET INCLISIRAN Novartis marketed Proprotein convertase subtilisin/kexin type 9 2021-01-01
Praluent ALIROCUMAB Sanofi marketed PCSK9 Inhibitor [EPC] Proprotein convertase subtilisin/kexin type 9 2015-01-01
Praluent Praluent Regeneron Pharmaceuticals marketed Proprotein convertase subtilisin/kexin type 9
Repatha® Repatha® Sejong General Hospital marketed PCSK9 inhibitor (monoclonal antibody) PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
Praluent (Alirocumab) Praluent (Alirocumab) Federico II University marketed PCSK9 inhibitor (monoclonal antibody) PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Leqvio — Competitive Intelligence Brief. https://druglandscape.com/ci/inclisiran. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: